<DOC>
	<DOCNO>NCT01156207</DOCNO>
	<brief_summary>Heart failure major health problem worldwide . Optimal treatment disable fatal condition may require functional characterization fail left ventricle ( LV ) interaction arterial system . Part physiological significance ventriculo-arterial coupling study experimentally clinically use framework ratio effective arterial elastance ( Ea ) end-systolic elastance ( Ees ) , limited clinical application . From central ascend aorta terminal arteriole , every segment arterial tree contribute arterial load interact impact LV performance systole diastole , lead atrial ventricular remodel hypertrophy , result development heart failure . On hand , ventricular systole complex coordination multi-directional myocardial fiber involve longitudinal contraction , circumferential shortening , radial thickening , twist , torsion , so-called LV deformation . The purpose present study investigate relationship different component hemodynamic load arterial abnormality different component LV myocardial deformation regional LV function , modulate effect endothelial progenitor cell ( EPCs ) ventriculo-arterial coupling , therapeutic effect aliskiren component hemodynamic load LV myocardial deformation coupling . The investigator also investigate whether ventriculo-arterial coupling , EPCs , add-on therapy aliskiren predict cardiovascular outcome .</brief_summary>
	<brief_title>Significance Regional Ventriculo-arterial Coupling Patients With Chronic Heart Failure</brief_title>
	<detailed_description>In propose 3-year project , hypothesize different component arterial load couple different component LV function . The regional ventriculo-arterial coupling may important pathogenesis heart failure ventricular remodeling , prediction future cardiovascular event . Therapies target may play role prevention treatment heart failure . Therefore , study least 120 patient chronic heart failure ( NYHA Class II-IV ) randomly receive direct renin inhibitor , aliskiren , placebo 6 month top standard therapy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Outpatients ≥ 18 year age , male female . Female patient must either postmenopausal one year , surgically sterile , use effective contraceptive method oral contraceptive , barrier method spermicide intrauterine device . 2 . Patients diagnosis chronic heart failure ( NYHA Class IIIV ) reduce systolic function : LVEF ≤ 45 % Visit 1 ( local measurement , measure within past 6 month assess echocardiogram , MUGA , CT scan , MRI ventricular angiography ) . 3 . NTpro BNP ≥ 600pg/ml ( BNP ≥ 150 pg/ml ) Visit 1 NTpro BNP ≥ 450 pg/mL ( BNP ( ≥ 100 pg/ml ) hospitalization HF within last 12 month 4 . Patients must stable dose either ACE inhibitor ARB least 4 week prior Visit 1 . 5 . Patients must treat beta blocker , unless contraindicate tolerated , stable dose least 4 week prior Visit 1 . 6 . Patients document sinus rhythm Visit 1 . 1 . History hypersensitivity study drug . 2 . Patients require treatment ACEI ARB . 3 . Current acute decompensated HF ( exacerbation chronic HF manifest sign &amp; symptom may require IV therapy ) . 4 . Symptomatic hypotension and/or le 100 mmHg time screen less 90 mmHg time randomization . 5. eGFR &lt; 30 ml/min/1.73m2 measure MDRD formula Visit 1 ( screen ) , &gt; 25 % decrease 14 day active runin period . 6 . Serum potassium &gt; 5.0 mmol/L screening ( Visit 1 ) . 7 . Acute coronary syndrome , stroke , transient ischemic attack , cardiac , carotid major vascular surgery , percutaneous coronary intervention ( PCI ) carotid angioplasty , within past 3 month prior visit 1 . 8 . Coronary carotid artery disease likely require surgical percutaneous intervention within 6 month Visit 1 . 9 . Patients active unstable bronchospasm asthma ( patient must stable regimen respiratory medication 1 month prior Visit 1 ) . 10 . Right heart failure due severe pulmonary disease . 11 . Diagnosis peripartum chemotherapy induce cardiomyopathy within 12 month prior visit 1 . 12 . Patients history heart transplant transplant list leave ventricular assistance device ( LVAD device ) . 13 . Documented ventricular arrhythmia syncopal episode within past 3 month , prior visit 1 , untreated . 14 . Symptomatic bradycardia second third degree heart block without pacemaker . 15 . Implantation CRT ( cardiac resynchronization therapy ) device within prior 3 month visit 1 intent implant CRT device . 16 . Presence hemodynamically significant mitral and/or aortic valve disease , except mitral regurgitation secondary leave ventricular dilatation . 17 . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic subaortic stenosis . 18 . Severe primary pulmonary , renal hepatic disease . 19 . Presence disease life expectancy &lt; 1 year . 20 . Chronic longterm requirement NSAIDs ( high dose ) COX2 inhibitor , exception aspirin dos use CV prophylaxis ( ≤325 mg o.d. ) . 21 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug 22 . Subjects get pregnant pregnant within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>To establish couple component arterial load ( component LV myocardial deformation baseline 6 month randomization .</keyword>
	<keyword>To establish role EPCs modulation component arterial load LV myocardial deformation couple .</keyword>
</DOC>